TrovaGene, Inc. (NASDAQ:TROV) shares dropped 6.5% during trading on Thursday . The stock traded as low as $0.41 and last traded at $0.43. Approximately 984,873 shares traded hands during mid-day trading, an increase of 75% from the average daily volume of 562,830 shares. The stock had previously closed at $0.46.

TROV has been the topic of several recent analyst reports. Maxim Group set a $4.00 price target on TrovaGene and gave the stock a “buy” rating in a research report on Wednesday, October 18th. cut TrovaGene from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th.

TrovaGene (NASDAQ:TROV) last released its earnings results on Thursday, November 9th. The medical research company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. The firm had revenue of $0.12 million for the quarter.

Several institutional investors have recently made changes to their positions in TROV. LMR Partners LLP bought a new position in shares of TrovaGene during the second quarter worth about $151,000. Susquehanna International Group LLP boosted its position in TrovaGene by 2,781.0% during the second quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock valued at $174,000 after purchasing an additional 133,240 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in TrovaGene by 1,079.5% during the second quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock valued at $351,000 after purchasing an additional 254,601 shares during the last quarter. Institutional investors own 13.92% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at

About TrovaGene

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with Analyst Ratings Network's FREE daily email newsletter.